LEXX has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
LEXX has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
Lexaria Bioscience's adjusted free cash flow per share for the three months ended in Feb. 2024 was $-0.063. Add all the adjusted free cash flow per share for the past 10 years together and divide the count will get our Cyclically Adjusted FCF per Share, which is $-1.07 for the trailing ten years ended in Feb. 2024.
During the past 3 years, the average Cyclically Adjusted FCF Growth Rate was -5.20% per year. During the past 5 years, the average Cyclically Adjusted FCF Growth Rate was -2.30% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted FCF Growth Rate using Cyclically Adjusted FCF per Share data.
During the past 13 years, the highest 3-Year average Cyclically Adjusted FCF Growth Rate of Lexaria Bioscience was 32.40% per year. The lowest was -5.20% per year. And the median was 1.10% per year.
As of today (2024-05-25), Lexaria Bioscience's current stock price is $3.12. Lexaria Bioscience's Cyclically Adjusted FCF per Share for the quarter that ended in Feb. 2024 was $-1.07. Lexaria Bioscience's Cyclically Adjusted Price-to-FCF of today is .
The historical data trend for Lexaria Bioscience's Cyclically Adjusted FCF per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Lexaria Bioscience Quarterly Data | ||||||||||||||||||||
May19 | Aug19 | Nov19 | Feb20 | May20 | Aug20 | Nov20 | Feb21 | May21 | Aug21 | Nov21 | Feb22 | May22 | Aug22 | Nov22 | Feb23 | May23 | Aug23 | Nov23 | Feb24 | |
Cyclically Adjusted FCF per Share | Get a 7-Day Free Trial | -0.95 | -1.02 | -1.06 | -1.09 | -1.07 |
For the Biotechnology subindustry, Lexaria Bioscience's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Lexaria Bioscience's Cyclically Adjusted Price-to-FCF distribution charts can be found below:
* The bar in red indicates where Lexaria Bioscience's Cyclically Adjusted Price-to-FCF falls into.
E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted FCF per Share and the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years.
What is Cyclically Adjusted FCF per Share? How do we calculate Cyclically Adjusted FCF per Share?
Cyclically Adjusted FCF per Share is the average of the inflation adjusted Free Cash Flow per Share of a company over the past 10 years. Let's use an example to explain.
If we want to calculate the Cyclically Adjusted FCF per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the free cash flow per share from 2001 through 2010.
We adjusted the 2001 free cash flow per share data with the total inflation from 2001 through 2010 to the equivalent free cash flow in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's free cash flow is $1 a share in 2001, then the 2001's equivalent free cash flow in 2010 is $1.4 a share. If Wal-Mart's free cash flow is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 free cash flow in 2010 is $1.35. So on and so forth, you get the equivalent free cash flow per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted FCF per Share.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
For example, Lexaria Bioscience's adjusted Free Cash Flow per Share data for the three months ended in Feb. 2024 was:
Adj_FreeCashFlowPerShare | = | Free Cash Flow per Share | / | CPI of Feb. 2024 (Change) | * | Current CPI (Feb. 2024) |
= | -0.063 | / | 125.4675 | * | 125.4675 | |
= | -0.063 |
Current CPI (Feb. 2024) = 125.4675.
Lexaria Bioscience Quarterly Data
Free Cash Flow per Share | CPI | Adj_FreeCashFlowPerShare | |
201404 | -0.146 | 98.920 | -0.185 |
201407 | -0.190 | 99.315 | -0.240 |
201411 | -0.202 | 99.078 | -0.256 |
201502 | -0.307 | 99.078 | -0.389 |
201505 | -0.296 | 100.263 | -0.370 |
201508 | -0.398 | 100.579 | -0.496 |
201511 | -0.145 | 100.421 | -0.181 |
201602 | -0.059 | 100.421 | -0.074 |
201605 | -0.072 | 101.765 | -0.089 |
201608 | -0.171 | 101.686 | -0.211 |
201611 | -0.067 | 101.607 | -0.083 |
201702 | -0.261 | 102.476 | -0.320 |
201705 | -0.299 | 103.108 | -0.364 |
201708 | -0.158 | 103.108 | -0.192 |
201711 | -0.234 | 103.740 | -0.283 |
201802 | -0.263 | 104.688 | -0.315 |
201805 | -0.248 | 105.399 | -0.295 |
201808 | -0.355 | 106.031 | -0.420 |
201811 | -0.288 | 105.478 | -0.343 |
201902 | -0.363 | 106.268 | -0.429 |
201905 | -0.499 | 107.927 | -0.580 |
201908 | -0.294 | 108.085 | -0.341 |
201911 | -0.213 | 107.769 | -0.248 |
202002 | -0.283 | 108.559 | -0.327 |
202005 | -0.247 | 107.532 | -0.288 |
202008 | -0.218 | 108.243 | -0.253 |
202011 | -0.272 | 108.796 | -0.314 |
202102 | -0.226 | 109.745 | -0.258 |
202105 | -0.241 | 111.404 | -0.271 |
202108 | -0.206 | 112.668 | -0.229 |
202111 | -0.214 | 113.932 | -0.236 |
202202 | -0.222 | 115.986 | -0.240 |
202205 | -0.218 | 120.016 | -0.228 |
202208 | -0.206 | 120.569 | -0.214 |
202211 | -0.215 | 121.675 | -0.222 |
202302 | -0.212 | 122.070 | -0.218 |
202305 | -0.283 | 124.045 | -0.286 |
202308 | -0.208 | 125.389 | -0.208 |
202311 | -0.135 | 125.468 | -0.135 |
202402 | -0.063 | 125.468 | -0.063 |
Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.
If a company grows much fast than inflation, Cyclically Adjusted FCF per Share may underestimate the company's free cash flow. Cyclically Adjusted Price-to-FCF can seem to be too high even the actual Price-to-Free-Cash-Flow is low.
For the Cyclically Adjusted Price-to-FCF, the free cash flow per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/FCF calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted Price-to-FCF is also called CAPFCF Ratio.
The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF. The Cyclically Adjusted FCF per Share is the average of the inflation adjusted free cash flow per share of a company over the past 10 years.
Cyclically Adjusted Price-to-FCF works better for cyclical companies. It gives you a better idea on the company's real free cash flow value.
Thank you for viewing the detailed overview of Lexaria Bioscience's Cyclically Adjusted FCF per Share provided by GuruFocus.com. Please click on the following links to see related term pages.
Catherine C. Turkel | director | 19900 MACARTHUR BLVD., SUITE 550, IRVINE CA 92612 |
Gregory Downey | officer: Chief Financial Officer | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Christopher Bunka | director, 10 percent owner, officer: CEO | 1924 BIRKDALE AVE, KELOWNA A1 V1P1R7 |
Vanessa Carle | officer: Secretary | 100 - 740 MCCURDY ROAD, KELOWNA A1 V1X 2P7 |
Reese Albert L Jr | director | |
Brian W. Quigley | director | 100 740 MCCURDY ROAD, KELOWNA A1 23230 |
William Edward Mckechnie | director | 305 MARGARET AVENUE, KITCHENER A6 N2H 6S4 |
Allan Horst Spissinger | officer: CFO | 8131 198A STREET, LANGLEY A1 V2Y 1Y6 |
John Martin Docherty | director, 10 percent owner | 23 MIKELEN DRIVE, PORT PERRY A6 L9L 1V1 |
Baljinder Bhullar | director, officer: CFO | 604 - 700 WEST PENDER, VANCOUVER A1 V6C 1G8 |
Nicholas W Baxter | director | 220 SPRINGFIELD ROAD, ABERDEEN, ABERDEENSHIRE, SCOTLAND X0 AB15 6AU |
Dustin Arthur Elford | director | 888 - 609 WEST HASTINGS STREET, VANCOUVER A1 V6B 4W4 |
Thomas James Ihrke | officer: Sr. VP, Business Development | 38 KRIER LANE, MOUNT PLEASANT SC 29464 |
David Demartini | director, 10 percent owner | 11714 SPRIGGS WAY, HOUSTON TX 77024 |
Leonard Macmillan | director, officer: Vice President - Corp Develop | SUITE 302, 125A - 1030 DENMAN STREET, VANCOUVER A1 V6G 2M6 |
From GuruFocus
By ACCESSWIRE • 08-02-2023
By ACCESSWIRE • 01-04-2024
By ACCESSWIRE • 07-28-2023
By ACCESSWIRE ACCESSWIRE • 05-23-2023
By ACCESSWIRE • 01-16-2024
By ACCESSWIRE ACCESSWIRE • 04-24-2023
By ACCESSWIRE ACCESSWIRE • 05-18-2023
By ACCESSWIRE ACCESSWIRE • 05-11-2023
By ACCESSWIRE • 06-22-2023
By ACCESSWIRE • 08-09-2023